Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04394442
  4. Details
NCT04394442 Clinical Trial

Hydroxychloroquine in COVID-19 Patients

COVID-19 Clinical Trial

Official title:
Use of Hydroxychloroquine in Patients With COVID-19: A Randomized Controlled Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04394442
Other study ID # SNH1352020
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date March 21, 2020
Est. completion date August 2020

Study information
Verified date May 2020
Source Zagazig University
Contact Samah M Lutfy, MD
Phone +966581244415
Email omar1star2008@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Many reports argued about the possible beneficial effects of Hydroxychloroquine in treating COVID-19 patients and this study was designed to investigate this claim

Recruitment information / eligibility
Status Recruiting
Enrollment 200
Est. completion date August 2020
Est. primary completion date August 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

Confirmed cases of SARS-CoV-2 by PCR

Exclusion Criteria:

less than 18 years old known hypersensitivity to the drug

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Hydroxychloroquine
400mg BD first day then 200 mg BD for 5 days

Locations
Country Name City State
Saudi Arabia SNH Mecca

Sponsors (1)
Lead Sponsor Collaborator
Samah Lutfy

Country where clinical trial is conducted

Saudi Arabia, 

Outcome
Type Measure Description Time frame Safety issue
Primary time to viral clearance PCR will be done every 72 h day till 2 consecutive negative PCR tests(24h apart) which is the viral clearance.The time between randomization and viral clearance is the viral clearance time 21 days after patients randomization
Primary % of mortality total number of deaths divided by total number of the group 60 days after randomization
Secondary Length of stay time from patients randomization till discharge 60 days after randomization
Secondary time to be afebrile time from randomization till day of fever subsiding 60 days after randomization
Secondary need for mechanical ventilation %of deteriorated patients necessitates mechanical ventilation 60 days after randomization
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure